Mesothelioma Treatment Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Mesothelioma Treatment Market: by Drug Class (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), By Application (Pleural Mesothelioma and Peritoneal Mesothelioma), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography ((North America, Latin America, Europe, Middle East and Africa, Asia Pacific)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

mesothelioma treatment market is expected to grow at a CAGR of 8.7% during CAGR 2021 to 2027. Mesothelioma is a rare and aggressive form of cancer that occurs in the thin layer tissue that covers the majority of the internal organs. Mesothelioma most often affects the tissue that surrounds the lungs (pleura), which is called pleural mesothelioma. Other, rarer types of mesothelioma affect tissue in the abdomen (peritoneal mesothelioma), around the heart and around the testicles. Pleural mesothelioma is the most common type of mesothelioma. Mesothelioma primarily caused by the inhalation of asbestos fibers, can be diagnosed in older individuals who worked with asbestos products in an industrial setting as there is no cure currently exists, mesothelioma patients can usually improve their prognosis through some form of treatment available. Chemotherapy is a crucial component of palliative care. AstraZeneca, for example, is active in the research and development of medicines for malignant mesothelioma. Durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716 are all major pipeline medicines. Because of the rising incidence rate, rising air pollution, rising senior population, and rising healthcare cost, the malignant mesothelioma market is expected to see significant expansion in the near future. Moreover, throughout the projected period, the development of novel therapies and the introduction of advanced treatment options are expected to present attractive potential prospects for the malignant mesothelioma market. However, the mesothelioma market is constrained by a long latent period between development and symptom, a lack of effective treatment, and a low surveillance rate.

Mesothelioma Treatment Market

MARKET SUMMARY
-
8.7% CAGR
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR– 8.7%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Mesothelioma Treatment Market

  • The report on global Mesothelioma Treatment Market gives historical, current, and future market sizes (US$ Bn) on the basis of drug class, application, route of administration, distribution channel and geography.
  • Mesothelioma Treatment Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Teva Pharmaceuticals (Israel)
  • Boehringer Ingelheim GmbH (Germany)
  • Mylan N.V. (U.S)
  • Fresenius Kabi AG (Germany)
  • Sun Pharmaceuticals Industries Ltd. (India)
Dynamics

Mesothelioma Treatment Market

Out of all types of mesothelioma, malignant pleural mesothelioma segment is anticipated to grow at significant rate and accounts for 70% of all mesothelioma cases followed by malignant peritoneal mesothelioma which accounts 15-20% of all mesothelioma cases. Many companies are focusing on the collaborations in order to study the combinations of various drugs. The combination therapies are improving the survival rates which is encouraging the R&D activities. According to the Cancer Research UK, 1 in every 140 men and 1 in every 710 women are diagnosed with malignant mesothelioma. The increasing cases of malignant mesothelioma are adding fuel to the mesothelioma treatment market growth.


North-America got significant share

Mesothelioma Treatment Market

Geographically, global mesothelioma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Asia-Pacific dominates the market due to the growing prevalence of mesothelioma in the region. The increasing geriatric population is also driving the growth of the market. The poor reimbursement policies may hamper the growth of the global mesothelioma treatment market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report covers exhaustive regional information, that includes North America, Asia-Pacific, Latin America and Middle East and Africa.
  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Mesothelioma Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Teva Pharmaceuticals (Israel)
  • Boehringer Ingelheim GmbH (Germany)
  • Mylan N.V. (U.S)
  • Fresenius Kabi AG (Germany)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Concordia International Corp. (U.K)
  • Kyowa Hakko Kirin Co Ltd. (Japan)
  • MolMed SpA (Italy)
  • Ono Pharmaceutical Co. Ltd. (Japan)
  • Nichi-Iko Pharmaceutical Co. (Japan)

Description

mesothelioma treatment market is expected to grow at a CAGR of 8.7% during CAGR 2021 to 2027. Mesothelioma is a rare and aggressive form of cancer that occurs in the thin layer tissue that covers the majority of the internal organs. Mesothelioma most often affects the tissue that surrounds the lungs (pleura), which is called pleural mesothelioma. Other, rarer types of mesothelioma affect tissue in the abdomen (peritoneal mesothelioma), around the heart and around the testicles. Pleural mesothelioma is the most common type of mesothelioma. Mesothelioma primarily caused by the inhalation of asbestos fibers, can be diagnosed in older individuals who worked with asbestos products in an industrial setting as there is no cure currently exists, mesothelioma patients can usually improve their prognosis through some form of treatment available. Chemotherapy is a crucial component of palliative care. AstraZeneca, for example, is active in the research and development of medicines for malignant mesothelioma. Durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716 are all major pipeline medicines. Because of the rising incidence rate, rising air pollution, rising senior population, and rising healthcare cost, the malignant mesothelioma market is expected to see significant expansion in the near future. Moreover, throughout the projected period, the development of novel therapies and the introduction of advanced treatment options are expected to present attractive potential prospects for the malignant mesothelioma market. However, the mesothelioma market is constrained by a long latent period between development and symptom, a lack of effective treatment, and a low surveillance rate.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX